FDA PCAC Meeting July 23–24: 7 Peptides Under Review for 503A Compounding

The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to formally review seven peptides — BPC157, KPV, TB500, MOTSc, emideltide, epitalon, and Semax — for potential inclusion on the 503A Bulk Drug Substances List. FDA staff have already recommended against all seven. Here is what the review covers and what it means for the research community.

For research use only. Not for human consumption.